메뉴 건너뛰기




Volumn 17, Issue 4, 2013, Pages 699-714

Lipid-lowering agents and hepatotoxicity

Author keywords

Drug induced liver injury; Hepatotoxicity; Lipid lowering agents; Statins

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; CLARITHROMYCIN; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; CYCLOSPORIN; CYTOCHROME P450 3A4; DICLOFENAC; DIGOXIN; EZETIMIBE; FENOFIBRATE; FENOFIBRIC ACID; FLUINDOSTATIN; GEMFIBROZIL; ITRACONAZOLE; MEVINOLIN; NEFAZODONE; NICOTINAMIDE; NICOTINIC ACID; PITAVASTATIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TACROLIMUS; UNINDEXED DRUG;

EID: 84884939001     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2013.07.016     Document Type: Review
Times cited : (29)

References (55)
  • 1
    • 84860144206 scopus 로고    scopus 로고
    • American Association of Clinical Endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis
    • Jellinger P.S., Smith D.A., Mehta A.E., et al. American Association of Clinical Endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr Pract 2012, 18(Suppl 1):1-78.
    • (2012) Endocr Pract , vol.18 , Issue.SUPPL 1 , pp. 1-78
    • Jellinger, P.S.1    Smith, D.A.2    Mehta, A.E.3
  • 2
    • 81855224663 scopus 로고    scopus 로고
    • AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association
    • Smith S.C., Benjamin E.J., Bonow R.O., et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. JAm Coll Cardiol 2011, 58(23):2432-2446.
    • (2011) JAm Coll Cardiol , vol.58 , Issue.23 , pp. 2432-2446
    • Smith, S.C.1    Benjamin, E.J.2    Bonow, R.O.3
  • 3
    • 77951944375 scopus 로고    scopus 로고
    • The myth of statin-induced hepatotoxicity
    • Bader T. The myth of statin-induced hepatotoxicity. Am J Gastroenterol 2010, 105:978-980. 10.1038/ajg.2010.102.
    • (2010) Am J Gastroenterol , vol.105 , pp. 978-980
    • Bader, T.1
  • 4
    • 0026557541 scopus 로고
    • HMG-CoA reductase inhibitors
    • Hunninghake D.B. HMG-CoA reductase inhibitors. Curr Opin Lipidol 1992, 3:22-28.
    • (1992) Curr Opin Lipidol , vol.3 , pp. 22-28
    • Hunninghake, D.B.1
  • 5
    • 0037490080 scopus 로고    scopus 로고
    • Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis
    • Law M.R., Wald N.J., Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003, 326:1423.
    • (2003) BMJ , vol.326 , pp. 1423
    • Law, M.R.1    Wald, N.J.2    Rudnicka, A.R.3
  • 6
    • 77956025285 scopus 로고    scopus 로고
    • Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians
    • Rzouq F.S., Volk M.L., Hatoum H.H., et al. Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians. Am J Med Sci 2010, 340:89-93.
    • (2010) Am J Med Sci , vol.340 , pp. 89-93
    • Rzouq, F.S.1    Volk, M.L.2    Hatoum, H.H.3
  • 7
    • 2342565003 scopus 로고    scopus 로고
    • Statins and liver toxicity: a meta-analysis
    • De Denus S., Spinler S.A., Miller K., et al. Statins and liver toxicity: a meta-analysis. Pharmacotherapy 2004, 24:584-591.
    • (2004) Pharmacotherapy , vol.24 , pp. 584-591
    • De Denus, S.1    Spinler, S.A.2    Miller, K.3
  • 8
    • 33645881669 scopus 로고    scopus 로고
    • Statin safety: a systematic review
    • Law M., Rudnicka A.R. Statin safety: a systematic review. Am J Cardiol 2006, 97(8A):52C-60C.
    • (2006) Am J Cardiol , vol.97 , Issue.8 A
    • Law, M.1    Rudnicka, A.R.2
  • 9
    • 0026088892 scopus 로고
    • Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia
    • Bradford R.H., Shear C.L., Chremos A.N., et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991, 151(1):43-49.
    • (1991) Arch Intern Med , vol.151 , Issue.1 , pp. 43-49
    • Bradford, R.H.1    Shear, C.L.2    Chremos, A.N.3
  • 10
    • 0027987849 scopus 로고
    • Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
    • Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344(8934):1383-1389.
    • (1994) Lancet , vol.344 , Issue.8934 , pp. 1383-1389
  • 11
    • 65749097599 scopus 로고    scopus 로고
    • Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people
    • MRC/BHF Heart Protection Study Collaborative Group
    • MRC/BHF Heart Protection Study Collaborative Group, Armitage J., Bowman L., Collins R., et al. Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people. BMC Clin Pharmacol 2009, 9:6.
    • (2009) BMC Clin Pharmacol , vol.9 , pp. 6
    • Armitage, J.1    Bowman, L.2    Collins, R.3
  • 12
    • 0028883828 scopus 로고
    • Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
    • West of Scotland Coronary Prevention Study Group (WOS) et al.
    • Shepherd J., Cobbe S.M., Ford I., for the West of Scotland Coronary Prevention Study Group (WOS), et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. NEngl J Med 1995, 333:1301-1307.
    • (1995) NEngl J Med , vol.333 , pp. 1301-1307
    • Shepherd, J.1    Cobbe, S.M.2    Ford, I.3
  • 13
    • 0032487931 scopus 로고    scopus 로고
    • The Long-term Intervention with Pravastatin in Ischemic Disease Group (LIPID). Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
    • The Long-term Intervention with Pravastatin in Ischemic Disease Group (LIPID). Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. NEngl J Med 1998, 339:1349-1357.
    • (1998) NEngl J Med , vol.339 , pp. 1349-1357
  • 14
    • 0342981862 scopus 로고    scopus 로고
    • The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
    • Cholesterol and Recurrent Events Trial Investigators (CARE) et al.
    • Sacks F.M., Pfeffer M.A., Moye L.A., for the Cholesterol and Recurrent Events Trial Investigators (CARE), et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. NEngl J Med 1996, 335:1001-1009.
    • (1996) NEngl J Med , vol.335 , pp. 1001-1009
    • Sacks, F.M.1    Pfeffer, M.A.2    Moye, L.A.3
  • 15
    • 53549104055 scopus 로고    scopus 로고
    • The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care
    • Garcia-Rodriguez L.A., Masso-Gonzalez E.L., Wallander M.A., et al. The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care. Pharmacoepidemiol Drug Saf 2008, 17:943-952.
    • (2008) Pharmacoepidemiol Drug Saf , vol.17 , pp. 943-952
    • Garcia-Rodriguez, L.A.1    Masso-Gonzalez, E.L.2    Wallander, M.A.3
  • 16
    • 36749013849 scopus 로고    scopus 로고
    • Atorvastatin: a safety and tolerability profile
    • Arca M. Atorvastatin: a safety and tolerability profile. Drugs 2007, 67(Suppl 1):63-69.
    • (2007) Drugs , vol.67 , Issue.SUPPL 1 , pp. 63-69
    • Arca, M.1
  • 17
    • 34547559566 scopus 로고    scopus 로고
    • Impact of statin dosing intensity on transaminase and creatine kinase
    • Dale K.M., White C.M., Henyan N.N., et al. Impact of statin dosing intensity on transaminase and creatine kinase. Am J Med 2007, 120(8):706-712.
    • (2007) Am J Med , vol.120 , Issue.8 , pp. 706-712
    • Dale, K.M.1    White, C.M.2    Henyan, N.N.3
  • 18
    • 29244483080 scopus 로고    scopus 로고
    • Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients
    • Newman C., Tsai J., Szarek M., et al. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol 2006, 97(1):61-67.
    • (2006) Am J Cardiol , vol.97 , Issue.1 , pp. 61-67
    • Newman, C.1    Tsai, J.2    Szarek, M.3
  • 19
    • 34447627450 scopus 로고    scopus 로고
    • Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials
    • Alsheikh-Ali A.A., Maddukuri P.V., Han H., et al. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. JAm Coll Cardiol 2007, 50:409-418.
    • (2007) JAm Coll Cardiol , vol.50 , pp. 409-418
    • Alsheikh-Ali, A.A.1    Maddukuri, P.V.2    Han, H.3
  • 20
    • 33645870418 scopus 로고    scopus 로고
    • Statin safety: lessons from new drug applications for marketed statins
    • Jacobson T.A. Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol 2006, 97(8A):44C-51C.
    • (2006) Am J Cardiol , vol.97 , Issue.8 A
    • Jacobson, T.A.1
  • 21
    • 0034048191 scopus 로고    scopus 로고
    • Defining patient risks from expanded preventive therapies
    • Tolman K.G. Defining patient risks from expanded preventive therapies. Am J Cardiol 2000, 85:15E-19E.
    • (2000) Am J Cardiol , vol.85
    • Tolman, K.G.1
  • 22
    • 84855970707 scopus 로고    scopus 로고
    • Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing
    • Björnsson E., Jacobsen E.I., Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. JHepatol 2012, 56(2):374-380. 10.1016/j.jhep.2011.07.023.
    • (2012) JHepatol , vol.56 , Issue.2 , pp. 374-380
    • Björnsson, E.1    Jacobsen, E.I.2    Kalaitzakis, E.3
  • 23
    • 2942705774 scopus 로고    scopus 로고
    • Safety of statins: focus on clinical pharmacokinetics and drug interactions
    • Bellosta S., Paoletti R., Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004, 109(23 Suppl 1):III50-III57.
    • (2004) Circulation , vol.109 , Issue.23 SUPPL 1 , pp. 350-357
    • Bellosta, S.1    Paoletti, R.2    Corsini, A.3
  • 24
    • 7044237064 scopus 로고    scopus 로고
    • Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors
    • Jacobson T.A. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 2004, 94(9):1140-1146.
    • (2004) Am J Cardiol , vol.94 , Issue.9 , pp. 1140-1146
    • Jacobson, T.A.1
  • 25
    • 10744229858 scopus 로고    scopus 로고
    • Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial
    • Holdaas H., Fellström B., Jardine A.G., et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003, 361(9374):2024-2031.
    • (2003) Lancet , vol.361 , Issue.9374 , pp. 2024-2031
    • Holdaas, H.1    Fellström, B.2    Jardine, A.G.3
  • 26
    • 77949312879 scopus 로고    scopus 로고
    • Statins improve ALT values in chronic hepatitis C patients with abnormal values
    • Madhoun M.F., Bader T. Statins improve ALT values in chronic hepatitis C patients with abnormal values. Dig Dis Sci 2010, 55:870-871.
    • (2010) Dig Dis Sci , vol.55 , pp. 870-871
    • Madhoun, M.F.1    Bader, T.2
  • 27
    • 33745591910 scopus 로고    scopus 로고
    • Incidence of statin hepatotoxicity in patients with hepatitis C
    • [quiz: 806]
    • Khorashadi S., Hasson N.K., Cheung R.C. Incidence of statin hepatotoxicity in patients with hepatitis C. Clin Gastroenterol Hepatol 2006, 4(7):902-907. [quiz: 806].
    • (2006) Clin Gastroenterol Hepatol , vol.4 , Issue.7 , pp. 902-907
    • Khorashadi, S.1    Hasson, N.K.2    Cheung, R.C.3
  • 28
    • 44949165396 scopus 로고    scopus 로고
    • Fluvastatin inhibits hepatitis C replication in humans
    • Bader T., Fazili J., Madhoun M., et al. Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol 2008, 103:1383-1389.
    • (2008) Am J Gastroenterol , vol.103 , pp. 1383-1389
    • Bader, T.1    Fazili, J.2    Madhoun, M.3
  • 29
    • 0036791192 scopus 로고    scopus 로고
    • Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day versus Daily Dosing of Atorvastatin Study (ADDAS)
    • Matalka M.S., Ravnan M.C., Deedwania P.C. Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day versus Daily Dosing of Atorvastatin Study (ADDAS). Am Heart J 2002, 144:674-677.
    • (2002) Am Heart J , vol.144 , pp. 674-677
    • Matalka, M.S.1    Ravnan, M.C.2    Deedwania, P.C.3
  • 30
    • 78649890465 scopus 로고    scopus 로고
    • Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study: a post hoc analysis
    • Athyros V.G., Tziomalos K., Gossios T.D., et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study: a post hoc analysis. Lancet 2010, 376:1916-1922.
    • (2010) Lancet , vol.376 , pp. 1916-1922
    • Athyros, V.G.1    Tziomalos, K.2    Gossios, T.D.3
  • 31
    • 78649824344 scopus 로고    scopus 로고
    • Liver tests are irrelevant when prescribing statins
    • Bader T. Liver tests are irrelevant when prescribing statins. Lancet 2010, 376:1882-1883.
    • (2010) Lancet , vol.376 , pp. 1882-1883
    • Bader, T.1
  • 32
    • 36348987648 scopus 로고    scopus 로고
    • Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial
    • Lewis J.H., Mortensen M.E., Zweig S., et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007, 46(5):1453-1463.
    • (2007) Hepatology , vol.46 , Issue.5 , pp. 1453-1463
    • Lewis, J.H.1    Mortensen, M.E.2    Zweig, S.3
  • 33
    • 33645888317 scopus 로고    scopus 로고
    • An assessment of statin safety by hepatologists
    • Cohen D., Anania F., Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol 2006, 97:C77-C81.
    • (2006) Am J Cardiol , vol.97
    • Cohen, D.1    Anania, F.2    Chalasani, N.3
  • 34
    • 0037300357 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment
    • Simonson S.G., Martin P.D., Mitchell P., et al. Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. Eur J Clin Pharmacol 2003, 58(10):669-675.
    • (2003) Eur J Clin Pharmacol , vol.58 , Issue.10 , pp. 669-675
    • Simonson, S.G.1    Martin, P.D.2    Mitchell, P.3
  • 35
    • 41549137855 scopus 로고    scopus 로고
    • Safety of statin therapy in patients with preexisting liver disease
    • Onofrei M.D., Butler K.L., Fuke D.C., et al. Safety of statin therapy in patients with preexisting liver disease. Pharmacotherapy 2008, 28(4):522-529.
    • (2008) Pharmacotherapy , vol.28 , Issue.4 , pp. 522-529
    • Onofrei, M.D.1    Butler, K.L.2    Fuke, D.C.3
  • 36
    • 65349094504 scopus 로고    scopus 로고
    • Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial
    • Abraldes J.G., Albillos A., Bañares R., et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 2009, 136:1651-1658.
    • (2009) Gastroenterology , vol.136 , pp. 1651-1658
    • Abraldes, J.G.1    Albillos, A.2    Bañares, R.3
  • 37
    • 20444371945 scopus 로고    scopus 로고
    • The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)
    • Garcia-Calvo M., Lisnock J., Bull H.G., et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci USA 2005, 102:8132-8137.
    • (2005) Proc Natl Acad Sci USA , vol.102 , pp. 8132-8137
    • Garcia-Calvo, M.1    Lisnock, J.2    Bull, H.G.3
  • 38
    • 0037111890 scopus 로고    scopus 로고
    • Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia
    • Gagné C., Bays H.E., Weiss S.R., et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002, 90:1084-1091.
    • (2002) Am J Cardiol , vol.90 , pp. 1084-1091
    • Gagné, C.1    Bays, H.E.2    Weiss, S.R.3
  • 39
    • 0038054346 scopus 로고    scopus 로고
    • Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies
    • Knopp R.H., Dujovne C.A., Le Beaut A., et al. Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies. Int J Clin Pract 2003, 57:363-368.
    • (2003) Int J Clin Pract , vol.57 , pp. 363-368
    • Knopp, R.H.1    Dujovne, C.A.2    Le Beaut, A.3
  • 40
    • 49349107489 scopus 로고    scopus 로고
    • Safety and efficacy of ezetimibe monotherapy in 1624 primary hypercholesterolaemic patients for up to 2 years
    • Dujovne C.A., Suresh R., McCrary Sisk C., et al. Safety and efficacy of ezetimibe monotherapy in 1624 primary hypercholesterolaemic patients for up to 2 years. Int J Clin Pract 2008, 62:1332-1336.
    • (2008) Int J Clin Pract , vol.62 , pp. 1332-1336
    • Dujovne, C.A.1    Suresh, R.2    McCrary Sisk, C.3
  • 41
    • 58149137193 scopus 로고    scopus 로고
    • Xavier Xiol Serious drug-induced liver disease secondary to ezetimibe
    • Castellote J., Ariza J., Rota R., et al. Xavier Xiol Serious drug-induced liver disease secondary to ezetimibe. World J Gastroenterol 2008, 14(32):5098-5099.
    • (2008) World J Gastroenterol , vol.14 , Issue.32 , pp. 5098-5099
    • Castellote, J.1    Ariza, J.2    Rota, R.3
  • 42
    • 27844560120 scopus 로고    scopus 로고
    • Ezetimibe/simvastatin (Vytorin) for hypercholesterolemia
    • Goldman-Levine J.D., Bohlman L.G. Ezetimibe/simvastatin (Vytorin) for hypercholesterolemia. Am Fam Physician 2005, 72:2081-2082.
    • (2005) Am Fam Physician , vol.72 , pp. 2081-2082
    • Goldman-Levine, J.D.1    Bohlman, L.G.2
  • 43
    • 75649136240 scopus 로고    scopus 로고
    • Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither
    • Conard S., Bays H., Leiter L.A., et al. Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither. Diabetes Obes Metab 2010, 12:210-218.
    • (2010) Diabetes Obes Metab , vol.12 , pp. 210-218
    • Conard, S.1    Bays, H.2    Leiter, L.A.3
  • 45
    • 0021350001 scopus 로고
    • The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease
    • The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984, 251(3):351-364.
    • (1984) JAMA , vol.251 , Issue.3 , pp. 351-364
  • 46
    • 0023879688 scopus 로고
    • The Lovastatin Study Group III. A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia
    • The Lovastatin Study Group III. A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. JAMA 1988, 260:359-366.
    • (1988) JAMA , vol.260 , pp. 359-366
  • 47
    • 0035071170 scopus 로고    scopus 로고
    • Colestipol-induced hepatotoxicity
    • Sirmans S.M., Beck J.K., Banh H.L., et al. Colestipol-induced hepatotoxicity. Pharmacotherapy 2001, 21(4):513-516.
    • (2001) Pharmacotherapy , vol.21 , Issue.4 , pp. 513-516
    • Sirmans, S.M.1    Beck, J.K.2    Banh, H.L.3
  • 48
    • 73949102364 scopus 로고    scopus 로고
    • Long-term safety and tolerability of colesevelam HCl in subjects with type 2 diabetes
    • Goldfine A.B., Fonseca V.A., Jones M.R., et al. Long-term safety and tolerability of colesevelam HCl in subjects with type 2 diabetes. Horm Metab Res 2010, 42:23-30.
    • (2010) Horm Metab Res , vol.42 , pp. 23-30
    • Goldfine, A.B.1    Fonseca, V.A.2    Jones, M.R.3
  • 49
    • 79955109060 scopus 로고    scopus 로고
    • Important considerations for treatment with dietary supplement versus prescription niacin products
    • Backes J.M., Padley R.J., Moriarty P.M. Important considerations for treatment with dietary supplement versus prescription niacin products. Postgrad Med 2011, 123:70-83.
    • (2011) Postgrad Med , vol.123 , pp. 70-83
    • Backes, J.M.1    Padley, R.J.2    Moriarty, P.M.3
  • 50
    • 0028057319 scopus 로고
    • Acomparison of the efficacy and toxic effects of sustained versus immediate release niacin in hypercholesterolemic patients
    • Mckenney J.M., Proctor J.D., Harris S., et al. Acomparison of the efficacy and toxic effects of sustained versus immediate release niacin in hypercholesterolemic patients. JAMA 1994, 271:672-677.
    • (1994) JAMA , vol.271 , pp. 672-677
    • Mckenney, J.M.1    Proctor, J.D.2    Harris, S.3
  • 51
    • 57149105884 scopus 로고    scopus 로고
    • Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study
    • Mohiuddin S.M., Pepine C.J., Kelly M.T., et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. Am Heart J 2009, 157(1):195-203.
    • (2009) Am Heart J , vol.157 , Issue.1 , pp. 195-203
    • Mohiuddin, S.M.1    Pepine, C.J.2    Kelly, M.T.3
  • 52
    • 72249115539 scopus 로고    scopus 로고
    • Does simvastatin cause more myotoxicity compared with other statins?
    • Backes J.M., Howard P.A., Ruisinger J.F., et al. Does simvastatin cause more myotoxicity compared with other statins?. Ann Pharmacother 2009, 43:2012-2020.
    • (2009) Ann Pharmacother , vol.43 , pp. 2012-2020
    • Backes, J.M.1    Howard, P.A.2    Ruisinger, J.F.3
  • 53
    • 0032788490 scopus 로고    scopus 로고
    • Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders
    • Murdock D.K., Murdock A.K., Murdock R.W., et al. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders. Am Heart J 1999, 138:151-155.
    • (1999) Am Heart J , vol.138 , pp. 151-155
    • Murdock, D.K.1    Murdock, A.K.2    Murdock, R.W.3
  • 54
    • 0030882897 scopus 로고    scopus 로고
    • Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia
    • Athyros V.G., Papageorgiou A.A., Hatzikonstandinou H.A., et al. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol 1997, 80:608-613.
    • (1997) Am J Cardiol , vol.80 , pp. 608-613
    • Athyros, V.G.1    Papageorgiou, A.A.2    Hatzikonstandinou, H.A.3
  • 55
    • 0033016149 scopus 로고    scopus 로고
    • The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment
    • Riegger G., Abletshauser C., Ludwig M., et al. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Atherosclerosis 1999, 144(1):263-270.
    • (1999) Atherosclerosis , vol.144 , Issue.1 , pp. 263-270
    • Riegger, G.1    Abletshauser, C.2    Ludwig, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.